Camilleri, Michael; Williams, Donald E. - In: PharmacoEconomics 17 (2000) 4, pp. 331-338
It has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in the 8 most industrialised countries. This paper reviews the data on calculations of direct costs. The true economic burden is unclear, as there are insufficient data on indirect...